Chinese firm CSPC Pharmaceutical has presented promising Phase I results for its first-in-class antibody-drug conjugate (ADC) SYS6010 in non-small cell lung cancer (NSCLC), but the contender is facing close competition from another domestic company.
The therapy conjugates an EGFR antibody with the topoisomerase I inhibitor JS-1 and is the first monospecific EGFR-targeting ADC to progress to the clinical stage in the NSCLC setting, including...
CSPC presented the advanced solid tumor results at the American Association for Cancer Research (AACR) annual meeting in Chicago on 27 April.
